文献速递临床免疫临床生化

基于上转换发光的高灵敏长片段心肌肌钙蛋白T免疫分析

Highly Sensitive Immunoassay for Long Forms of Cardiac Troponin T Using Upconversion Luminescence.
PubMed 文献 · Clin Chem · 2024-01-01

本研究开发了一种以UCNP为报告分子的两步夹心免疫分析法检测长片段cTnT,检测限0.40 ng/L、定量限1.79 ng/L,较既往TRF法分别低28倍和14倍。在NSTEMI(n=30)与ESRD(n=37)患者样本中,长片段/总cTnT比值鉴别两者的AUC达0.986(95%CI 0.967-1.000)。

要点

  • 新型UCNP免疫分析检测长片段cTnT,检测限0.40 ng/L、定量限1.79 ng/L。
  • Li-肝素血浆和EDTA血浆适用,血清不适用。
  • 长片段/总cTnT比值鉴别NSTEMI与ESRD的AUC为0.986。

核心结论

  • 利用上转换发光技术可建立高灵敏长片段cTnT免疫分析法,有望用于研究长片段cTnT作为AMI生物标志物的全部潜力。

研究设计与样本

  • 开发两步夹心型免疫分析,以UCNP为报告分子检测长片段cTnT,并测定检测限与定量限、评价线性和基质效应。
  • 用NSTEMI患者(n=30)和ESRD患者(n=37)临床样本评估性能,与既往TRF法长片段cTnT分析和商业化高敏cTnT分析比较。

主要发现

  • 新分析检测限为0.40 ng/L,较既往TRF长片段cTnT分析低28倍;定量限为1.79 ng/L,低14倍。
  • Li-肝素血浆和EDTA血浆适合作为样本基质,血清不适合。
  • ROC分析中,新分析测得的长片段/总cTnT比值鉴别NSTEMI与ESRD的AUC为0.986(95%CI,0.967-1.000)。

关键数值与推荐

  • 检测限0.40 ng/L,定量限1.79 ng/L。
  • 长片段/总cTnT比值鉴别NSTEMI与ESRD的AUC为0.986(95%CI,0.967-1.000)。

临床怎么用

  • 该高灵敏长片段cTnT分析法可用于临床样本检测,但适用基质为Li-肝素血浆和EDTA血浆,不适用血清。
  • 长片段/总cTnT比值可能有助于鉴别NSTEMI与ESRD,尚需进一步研究验证。

局限性

  • 临床样本仅来自NSTEMI(n=30)和ESRD(n=37)患者,样本量有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Long cardiac troponin T (cTnT) has been proposed to be a promising and more specific biomarker of acute myocardial infarction (AMI). As it represents a subfraction of circulating cTnT, detection of very low concentrations is a requirement. The aim of this study was to develop a novel, highly sensitive immunoassay for long cTnT. METHODS: A two-step sandwich-type immunoassay for long cTnT was developed, utilizing upconverting nanoparticles (UCNPs) as reporters. The limits of detection and quantitation were determined for the assay. Linearity and matrix effects were evaluated. Performance with clinical samples was assessed with samples from patients with non-ST elevation myocardial infarction (NSTEMI, n = 30) and end-stage renal disease (ESRD, n = 37) and compared to a previously developed time-resolved fluorescence (TRF)-based long cTnT assay and a commercial high-sensitivity cTnT assay. RESULTS: The novel assay reached a 28-fold lower limit of detection (0.40 ng/L) and 14-fold lower limit of quantitation (1.79 ng/L) than the previously developed TRF long cTnT assay. Li-heparin and EDTA plasma, but not serum, were found to be suitable sample matrixes for the assay. In a receiver operating characteristics curve analysis, the troponin ratio (long/total cTnT) determined with the novel assay showed excellent discrimination between NSTEMI and ESRD with an area under the curve of 0.986 (95% CI, 0.967-1.000). CONCLUSIONS: By utilizing upconversion luminescence technology, we developed a highly sensitive long cTnT assay. This novel assay can be a valuable tool for investigating the full potential of long cTnT as a biomarker for AMI. ClinicalTrials.gov Registration Number: NCT04465591.

来源:Clin Chem,查看原文。版权归原作者所有。

引用

  1. Salonen SM, Tuominen TJK, Raiko KIS, et al. Highly Sensitive Immunoassay for Long Forms of Cardiac Troponin T Using Upconversion Luminescence. Clin Chem. 2024. PMID: 38888909. doi:10.1093/clinchem/hvae075

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。